NON-SMALL CELL LUNG CANCER

This study tests a vaccine made from lung cancer cells, combined with an immune-boosting drug (N-803), to see if it can prevent non-small cell lung cancer from returning after surgery. About 30 adults with no signs of cancer after surgery will receive the vaccine as shots under t…

This study tests two targeted pills (encorafenib and binimetinib) in 63 Chinese adults with advanced non-small cell lung cancer that has a specific BRAF V600E gene change. Participants have not had prior treatments targeting this mutation. The main goal is to see if the combinati…

This early-phase study tests a new drug, amivantamab, combined with standard targeted therapies (TKIs) in 12 adults with advanced non-small cell lung cancer that has specific gene changes (ALK, ROS1, or RET). The goal is to see if the combination can overcome resistance that ofte…

This phase 3 trial tests whether adding radiation to a standard immunotherapy-plus-chemotherapy regimen can improve survival in people with advanced non-small cell lung cancer. About 327 participants with stage IIIB/IV disease will receive pembrolizumab and chemotherapy, with or …

This study offers continued treatment with lorlatinib for people with ALK- or ROS1-positive non-small cell lung cancer who are already benefiting from it in earlier Pfizer studies. The goal is to keep providing the drug while collecting more safety information. About 76 participa…

This study tests a precise, high-dose radiation treatment (SABR) for people with early-stage non-small cell lung cancer who also have interstitial lung disease (ILD), a condition that causes lung scarring. About 39 participants will be grouped by ILD severity to see how well the …

This study tested whether adding the drug abemaciclib to standard care helps people with stage IV lung cancer that has a specific KRAS mutation and has stopped responding to chemotherapy. About 450 adults took part, receiving either abemaciclib or another drug called erlotinib, p…

This study tests whether a shot under the skin (subcutaneous) of the immunotherapy drug pembrolizumab works as well as the standard IV infusion for people with advanced non-small cell lung cancer that has spread. About 67 participants will receive either the shot or the IV, and r…

This study tests two different dosing schedules of a subcutaneous (under-the-skin) form of the immunotherapy drug nivolumab, given together with intravenous ipilimumab and chemotherapy, in people with advanced or recurrent non-small cell lung cancer who have not had prior treatme…

This study compares a new drug, BL-B01D1, with the standard chemo docetaxel in people with advanced non-small cell lung cancer that has not responded to prior treatments. About 698 participants will be randomly assigned to receive either BL-B01D1 or docetaxel. The main goal is to…

This study tests whether thymosin alpha-1, an immune-boosting drug, helps people with advanced lung cancer complete a full year of immunotherapy after standard chemoradiation. About 114 participants will be randomly assigned to receive thymosin alpha-1 or not. The goal is to see …

This study tests the drug osimertinib in people with non-small cell lung cancer that has certain uncommon gene changes (EGFR mutations). Participants take the pill after their tumor is completely removed by surgery. The goal is to see if the drug helps keep the cancer from coming…

This study is for people with advanced solid tumors (like lung, bladder, or skin cancer) that have stopped responding to standard immunotherapy drugs called PD-1/PD-L1 inhibitors. Researchers are testing a new combination of immune-boosting drugs to see if they can shrink tumors …

This study tests a new drug, JDQ443, against a standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific mutation called KRAS G12C. Participants have already tried platinum chemo and immunotherapy. The goal is to see if JDQ443 can be…

This study tests a new drug called SI-B001 combined with chemotherapy in 69 adults with advanced non-small cell lung cancer that no longer responds to standard treatments. The goal is to see if the combination can shrink tumors or slow the disease. Participants must have a specif…

This study tests whether a new combination of two drugs (zimberelimab and domvanalimab) plus chemotherapy helps people with advanced non-small cell lung cancer live longer compared to the current standard treatment (pembrolizumab plus chemotherapy). About 1021 adults with untreat…

This study tests a combination of two drugs, alectinib and cobimetinib, in people with advanced ALK-positive non-small cell lung cancer. The goal is to find the safest dose and see how well the drugs shrink tumors. About 16 adults with stage IV cancer that has an ALK gene change …

This early-stage study tests a new daily pill, zongertinib, for people with advanced solid tumors (including lung cancer) that have HER2 gene changes. The first part finds the best dose, and the second part checks if the drug can shrink tumors. Participants stay on treatment as l…

This study tests whether adding an experimental drug (fianlimab) to standard immunotherapy (cemiplimab) and chemotherapy can better control advanced non-small cell lung cancer. About 950 adults who have not had prior treatment for advanced disease will receive either the triple c…

This early-stage study tests the safety and effectiveness of combining two drugs, abemaciclib and pembrolizumab, in 100 people with advanced non-small cell lung cancer or hormone receptor-positive, HER2-negative breast cancer that has spread. The goal is to see if the combination…

This study looks at whether having a cancer survivor's regular doctor work closely with their cancer team can better manage heart-related conditions like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers (like breast, prostate, or lung) an…

This study tests an experimental drug, zelenectide pevedotin, in people with advanced non-small cell lung cancer that has a specific genetic change called NECTIN4 amplification. Participants must have already tried at least one prior cancer treatment. The goal is to see if the dr…

This study tests a new drug combination (SI-B001 plus osimertinib) in people with advanced non-small cell lung cancer that has stopped responding to standard treatments. About 14 adults with specific genetic mutations will receive the combo to see if it shrinks tumors and how saf…

This study tests a combination of two immune-boosting drugs (zimberelimab and domvanalimab) as a first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. The goal is to see if the combo helps control the cancer longer tha…

This study tested a treatment plan for people with non-small cell lung cancer that has spread to a small number of other body sites (up to 3). The approach combines immunotherapy and chemotherapy with precise radiation to the cancer spots, followed by surgery or radiation to the …

This study tests a drug called atezolizumab in 60 people with advanced non-small cell lung cancer that has not been treated yet. The drug works by helping the immune system fight cancer cells. The main goal is to see how long people live and how long the cancer stays under contro…

This early-phase trial tests a new drug called BI-1910, alone or with pembrolizumab, in people with advanced solid tumors (like lung or liver cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug s…

This program gives patients with serious non-small cell lung cancer access to the drug capmatinib when no other treatments are available and they cannot join a clinical trial. It is for people whose doctors have requested the drug and who have no satisfactory alternative therapy.…

This study tests whether giving extra radiation to the most active parts of a lung tumor can reduce the chance of cancer returning in the chest. About 78 adults with advanced non-small cell lung cancer will receive either standard chemoradiotherapy or chemoradiotherapy with a tar…

This study compares a new targeted therapy pill (DZD9008) to standard chemotherapy in about 320 people with advanced non-small cell lung cancer that has a specific EGFR exon 20 insertion mutation. Participants are randomly assigned to receive either the pill or chemo. The main go…

This study tests whether combining the drug durvalumab with radiation therapy can slow down lung cancer growth in people with stage II or III non-small cell lung cancer. Unlike standard treatment, this approach skips chemotherapy. The goal is to see if more patients stay cancer-f…

This study looks at whether giving precise radiation (SBRT) to tumors that have just started to grow can help people with metastatic triple-negative breast cancer or non-small cell lung cancer live longer without their disease getting worse. About 107 adults are taking part. The …

This study tests whether giving the immunotherapy drug durvalumab along with standard chemotherapy before surgery or radiation can help people with stage IIB-IIIB non-small cell lung cancer. After initial treatment, participants either have surgery followed by more durvalumab, or…

This early-phase study tests a new drug called AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) into one treatment. The goal is to find the safest dose and see if it can shrink tumors in people with advanced cancers like melanoma, lung, and ovarian canc…

This early-stage trial tests a precise, high-dose radiation therapy for people with non-small cell lung cancer located near the center of the chest. The goal is to find the highest dose that can control the tumor while keeping the risk of serious side effects below 30%. About 30 …

This study tests a drug called sunvozertinib given before surgery for people with stage II to IIIB non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). The goal is to see if the drug can shrink tumors and improve outcomes. About 24 participants …

This study tests whether giving chemotherapy plus immunotherapy before surgery works better than chemotherapy alone for people with advanced non-small cell lung cancer that can still be removed. About 90 patients will take part. The main goal is to see if the combined treatment l…

This study tests a cancer-killing virus (VSV-IFNβ-NIS) combined with the immunotherapy drug pembrolizumab in people with advanced solid tumors, including non-small cell lung cancer, neuroendocrine cancer, and kidney cancer. The goal is to find the safest and most effective virus …

This study tested whether adding hydroxychloroquine (a malaria drug) to the standard targeted therapy erlotinib could delay or prevent drug resistance in people with advanced non-small cell lung cancer that has a specific EGFR mutation. About 76 participants received either erlot…

This study tests a new drug called amivantamab, which targets two proteins on lung cancer cells. It is given alone or with other treatments to people with advanced non-small cell lung cancer that has spread or cannot be removed. The goal is to find safe doses and see if the drug …

This study compares a new drug, SHR-A2009, with standard chemotherapy in about 500 adults with advanced EGFR-mutated non-small cell lung cancer that has worsened after EGFR-targeted treatment. The main goal is to see if SHR-A2009 delays cancer growth better than chemo. Participan…

This study tested a combination of two targeted drugs, tepotinib and osimertinib, in people with advanced non-small cell lung cancer whose tumors had a specific genetic change (MET amplification) and had stopped responding to the standard treatment osimertinib. The goal was to se…

This study tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus two rounds of chemotherapy as a first treatment for people with advanced lung cancer that has spread to the brain. The goal is to see if this approach can control the cancer in the brain for…

This study tested a combination of two targeted drugs, osimertinib and selumetinib, in 25 people with advanced non-small cell lung cancer that has a specific EGFR mutation. The goal was to see how well the drugs shrink tumors and delay cancer growth. Participants had not received…

This study tests whether combining two drugs, amivantamab and tepotinib, can help control non-small cell lung cancer with specific MET gene changes. About 3 adults with advanced lung cancer that cannot be removed by surgery will receive the drug combination. Researchers will moni…

This study tests whether adding the immunotherapy drug durvalumab to precise radiation therapy (SBRT) can better control early-stage non-small cell lung cancer compared to radiation alone. About 13 adults with stage I to IIIA lung cancer received the combination. The main goal is…

This study looks at whether adding a special type of radiation (SABR) to usual cancer therapy can help people with non-small cell lung cancer that has spread to only a few spots in the body. About 140 adults will be randomly assigned to get either standard treatment alone or stan…

This study tests whether adding the experimental drug SKB264 to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced non-small cell lung cancer whose tumors have a specific marker (PD-L1 positive). About 406 participants who have…

This early-stage trial tests an experimental drug called RC148, given alone or with other treatments, for people with advanced non-small cell lung cancer that has spread. The study involves 121 participants and aims to see if the drug shrinks tumors and how safe it is. It is for …

This study tested an experimental drug called PF-06801591, which helps the immune system attack cancer cells. It involved 155 adults with advanced solid tumors or non-small-cell lung cancer who had already tried other treatments. The goal was to check the drug's safety, how the b…

This study tests a combination of two drugs, nivolumab and ramucirumab, in people with advanced non-small cell lung cancer that has returned or spread. Participants must have already received immunotherapy. The main goal is to see if the combination can control the disease, meani…

This study tests whether giving the drug cemiplimab (alone or with another drug called fianlimab) before surgery can shrink tumors in people with lung, liver, or head/neck cancers. About 65 participants will receive the treatment and then have surgery. Researchers will check how …

This study tests whether adding an immunotherapy drug (atezolizumab) to a standard chemotherapy (paclitaxel) and a targeted therapy (bevacizumab) can help people with advanced non-squamous lung cancer whose disease has continued to grow after prior chemotherapy and immunotherapy.…

This study tests a new drug called LY4066434 in people with advanced solid tumors that have certain KRAS mutations. The main goal is to see if the drug is safe and tolerable when given alone or with other treatments. About 750 participants with cancers like pancreatic, lung, or c…

This study tests a new combination of three treatments—an immune-boosting injection (IL-2), targeted radiation, and the immunotherapy drug pembrolizumab—in adults with advanced lung, skin, kidney, or head and neck cancers that no longer respond to standard immunotherapy. The goal…

This study tests a new drug called DZD9008 (sunvozertinib) in people with advanced non-small cell lung cancer that has specific changes in the EGFR or HER2 genes and has stopped responding to other treatments. The goal is to check the drug's safety, side effects, and how well it …

This study looks at whether adding stereotactic radiotherapy (precise radiation) to standard targeted drug therapy can better control brain metastases in people with non-small cell lung cancer. About 202 participants who have a specific gene mutation (EGFR) and brain tumors that …

This phase 2 trial tests the drug T-DXd (Enhertu) in 27 adults with advanced HER2-mutant non-small cell lung cancer that has spread to the brain but is not causing symptoms. The main goal is to see how long the drug can keep brain tumors from growing. T-DXd is already approved fo…

This study compares a new drug, DS-1062a, to a standard chemotherapy (docetaxel) in about 605 adults with advanced or metastatic non-small cell lung cancer that has already been treated. The goal is to see if DS-1062a can better delay cancer growth and extend survival. Participan…

This study tests an experimental drug called entrectinib in people with advanced solid tumors that have certain gene changes (NTRK, ROS1, or ALK). The drug aims to shrink or control the cancer by blocking signals that help it grow. About 534 adults with various cancers, including…

This study tests whether adding high-dose vitamin C (ascorbate) to the usual treatment of radiation and chemotherapy (carboplatin and paclitaxel) helps control non-small cell lung cancer. About 43 participants received this combination therapy. The goal is to see if the vitamin C…

This study tests a two-step treatment for people with a specific type of lung cancer (EGFR-mutant, stages II to IIIB). First, patients take a targeted pill (almonertinib), then receive a combination of immunotherapy (adebrelimab) and chemotherapy. After these treatments, surgery …

This phase 3 study tests a new oral drug, PLB1004, against standard chemotherapy for people with advanced non-small-cell lung cancer that has a specific EGFR mutation (exon 20 insertion). About 327 adults with this rare, hard-to-treat cancer will be enrolled. The main goal is to …

This study tests a new drug called AB-106 in people with advanced non-small cell lung cancer that has a specific genetic change (ROS1 fusion). The goal is to see if the drug can shrink tumors and to check for side effects. About 173 adults will receive the drug and be monitored f…

This study tests whether adding the experimental drug uliledlimab to standard immunotherapy (sintilimab) and chemotherapy can help people with advanced non-small cell lung cancer live longer without their cancer growing. About 150 adults who have not had prior treatment for their…

This phase 3 study tests whether the experimental drug sacituzumab govitecan helps people with advanced non-small cell lung cancer live longer than the standard chemotherapy docetaxel. The trial includes 603 adults whose cancer worsened after platinum-based chemo and immunotherap…

This study is for people with advanced non-small cell lung cancer whose disease has gotten worse after treatment with immunotherapy (anti-PD-1/PD-L1 drugs). It tests several different drug combinations, chosen based on the specific biomarkers (genetic markers) found in each perso…

This study tests a drug called DFMO combined with the immunotherapy pembrolizumab in people with advanced non-small cell lung cancer that has a change in the STK11 gene. The goal is to find a safe dose and see if the combination shrinks tumors. About 45 adults will take part.

This study tests whether combining the drug tislelizumab with other experimental drugs, with or without chemotherapy, can shrink tumors in people with advanced non-small cell lung cancer who haven't had treatment yet. About 400 adults with either high or low PD-L1 levels will tak…

This early-stage study tests two drugs together—tepotinib and pembrolizumab—in people with advanced non-small cell lung cancer. The goal is to see if adding tepotinib can help pembrolizumab work better, especially in tumors that don't respond well to immunotherapy alone. About 19…

This study tests whether adding another drug (oleclumab or monalizumab) to the standard immunotherapy durvalumab can help people with stage III lung cancer that cannot be removed by surgery. About 1,050 adults who finished chemotherapy and radiation without their cancer getting w…

This study tests a new drug called ARRY-614 combined with standard immunotherapies (nivolumab or nivolumab+ipilimumab) in people with advanced solid tumors like lung, kidney, skin, and head/neck cancers. The first part finds a safe dose, and the second part checks if the combinat…

This study looks at people with advanced non-small cell lung cancer that has a specific EGFR gene change. After 3 weeks on the standard targeted drug osimertinib, those whose cancer still shows the gene change in their blood are randomly assigned to either keep taking osimertinib…

This study tests an experimental drug, telisotuzumab vedotin, in adults with a certain type of advanced lung cancer (c-Met+ non-small cell lung cancer) that has already been treated. The drug works like a guided missile, delivering a toxin directly to cancer cells that have a spe…

This phase 3 study tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy before and after surgery helps people with stage II or IIIA non-small cell lung cancer. About 453 participants will receive either tislelizumab plus chemo or a placebo plus chemo,…

This study tests a new three-drug combination (ADI-PEG 20, gemcitabine, and docetaxel) in people with small cell or non-small cell lung cancer whose disease has worsened after initial treatment. The first part of the study finds the safest dose, and the second part checks how wel…

This study tests an experimental drug called INBRX-106, given alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced solid tumors (like lung, head and neck, melanoma, stomach, kidney, or bladder cancer) that have stopped responding to standard treatment…

This phase 3 study tests whether adding chemotherapy to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for people with advanced non-small-cell lung cancer that has high levels of PDL1 (a protein that helps cancer hide from the immune system). About 349…

This study tests whether adding two new drugs (datopotamab deruxtecan and rilvegostomig) after surgery can keep stage I lung cancer from coming back. It is for people whose tumors have certain high-risk features or signs of cancer DNA in the blood. Participants will receive eithe…

This study tests whether a targeted drug called selpercatinib works better than standard chemotherapy for people with a specific type of advanced lung cancer (RET fusion-positive NSCLC). About 261 participants will receive either selpercatinib or chemo, and those on chemo whose c…

This study tests whether adding the targeted drug osimertinib to standard chemotherapy can help people with a certain type of advanced lung cancer (EGFR-mutant non-small cell lung cancer) whose disease has gotten worse after initial osimertinib treatment. About 98 participants wi…

This early-stage study tests an investigational drug called ABBV-400, alone or with another drug (bevacizumab), in about 520 adults with advanced solid tumors including lung, stomach, and colorectal cancers. The goal is to find the safest and most effective dose and see if it can…

This early-phase study tests a new drug, GDC-6036, in people with advanced cancers (like lung or colorectal) that have a specific KRAS G12C mutation. The main goals are to check safety and find the right dose, either alone or with other cancer treatments. About 500 participants w…

This study tests whether adding savolitinib to the standard drug osimertinib can shrink tumors or slow cancer growth in people with a specific type of advanced lung cancer (EGFR mutation-positive and MET amplified) that has worsened despite osimertinib treatment. About 30 adults …

This study tests an experimental drug called SKB264, given alone or with other treatments, for people with advanced or metastatic non-small cell lung cancer. The goal is to see if the drug is safe and can shrink tumors. About 356 adults with specific genetic types of lung cancer …

This study tests whether adding a special type of radiotherapy to standard chemotherapy and immunotherapy before surgery can help people with stage III lung cancer live longer without the cancer coming back. About 90 participants will receive one of three different radiation sche…

This study tests a new antibody drug, acasunlimab, in people with advanced solid tumors that have not responded to standard treatments. The first part checks safety and finds the best dose, while the second part tests how well it works alone or with other cancer drugs. About 429 …

This early-stage study tests a new drug, MK-2870, alone or with pembrolizumab (and sometimes chemotherapy) in Japanese adults with advanced solid tumors or a type of lung cancer. The main goal is to check safety and find the right dose. About 30 people will take part.

This study tests whether adding a new drug (uliledlimab) to an existing immunotherapy (toripalimab) works better than toripalimab alone or another standard drug (pembrolizumab) for people with advanced non-small cell lung cancer. Participants must have tumors with specific marker…

This study tests a combination of two drugs, ensartinib and bevacizumab, in people with advanced non-small cell lung cancer that has specific genetic changes (ALK rearrangement and TP53 mutation). The goal is to see if the combo can keep the cancer from growing for at least 12 mo…

This study tests an experimental daily pill, BDTX-1535, in about 200 adults with advanced non-small cell lung cancer or glioblastoma (a type of brain tumor). The drug targets specific EGFR mutations that make cancers resistant to other treatments. The goal is to find the safest d…

This study tests whether adding a new drug (relatlimab) to standard immunotherapy (nivolumab) and chemotherapy works better than nivolumab plus chemotherapy alone for people with advanced or recurrent non-small cell lung cancer. About 468 participants will receive one of the two …

This study tests an oral drug called selpercatinib in people with advanced solid tumors that have a specific RET gene change. The goal is to see if the drug is safe and can shrink tumors. About 857 adults with lung, thyroid, colon, or other cancers took part. The drug is taken by…

This study tests a new drug called RNDO-564, alone or with another drug (pembrolizumab), in people with advanced solid tumors (like lung, bladder, or breast cancer) that no longer respond to standard treatments. The main goals are to check safety, find the best dose, and see if t…

This study tests whether combining two targeted drugs, encorafenib and binimetinib, can shrink tumors in people with a specific genetic mutation (BRAF V600E) in advanced non-small cell lung cancer. About 119 participants will receive the drug combination. The main goal is to see …

This study tests a drug called sacituzumab govitecan combined with pembrolizumab and sometimes chemotherapy for people with advanced or metastatic non-small-cell lung cancer that has no targetable genetic changes. About 193 participants who have not had prior treatment for their …

This phase 3 study compares a new drug, BL-B01D1, with standard chemotherapy in 432 adults with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to EGFR-targeted pills. The main goal is to see if BL-B01D1 can delay cancer growth or …

This study tests whether adding the drug durvalumab to standard chemoradiation helps people with stage III lung cancer that cannot be removed by surgery. About 328 participants received either durvalumab or a placebo alongside their usual treatment. The main goal is to see if the…

This early-stage study tests two experimental drugs (botensilimab and balstilimab) that help the immune system fight cancer. It includes about 500 adults with advanced solid tumors like lung, ovarian, or colorectal cancer that haven't responded to standard treatments. The main go…

This early-stage study tests an experimental pill called HBI-2376 in people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have specific gene changes (KRAS or EGFR mutations). The main goals are to find the safest dose and understand how the drug moves t…

This study tests several treatments for people with stage III non-small cell lung cancer that cannot be removed by surgery. Researchers select therapies based on specific genetic markers (biomarkers) in each patient's tumor. The goal is to see if these targeted approaches can del…

This study tests an experimental drug called HFB200301, given alone or with another drug (tislelizumab), in adults with advanced solid tumors like stomach, kidney, or lung cancer. The goal is to find a safe dose and see how well people tolerate it. About 72 participants will take…

This study tests a combination of two drugs, tuvusertib and cemiplimab, in people with a type of lung cancer (non-squamous non-small cell) that has worsened after standard treatments like immunotherapy and chemotherapy. The goal is to see if the combination can shrink tumors or s…

This study tests a new drug called tobemstomig combined with chemotherapy against the standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that hasn't been treated before. The goal is to see if the new combination works better a…

This study tests whether adding ramucirumab to the standard drug osimertinib can help people with a specific type of advanced lung cancer (EGFR-mutant) live longer without their disease getting worse. About 160 adults with advanced or metastatic non-small cell lung cancer that ha…

This early-stage study tests a new drug, HBI-2438, in people with advanced cancers (like lung, colon, or pancreatic) that have a specific genetic mutation called KRAS G12C. The main goals are to find a safe dose and understand how the drug moves through the body. About 44 adults …

This study tests two treatment options for people with advanced ALK-positive non-small cell lung cancer who have not had treatment yet. One group gets the targeted drug brigatinib alone, and the other gets brigatinib plus chemotherapy. The goal is to see if the combination helps …

This study tested a new treatment plan for people with stage II or III non-small cell lung cancer. First, the main tumor in the lung was treated with a precise, high-dose radiation (SBRT). Then, the lymph nodes in the chest received standard radiation and chemotherapy, followed b…

This study compares a new drug, divarasib, with two existing drugs (sotorasib and adagrasib) in people with a specific genetic subtype of advanced non-small cell lung cancer (KRAS G12C). The goal is to see if divarasib works better at slowing cancer growth and improving survival.…

This early-phase study tests an experimental cell therapy called P-MUC1C-ALLO1 in 180 adults with advanced solid tumors (e.g., breast, ovarian, lung, pancreatic cancers) that have not responded to standard treatments. The therapy uses donor immune cells engineered to target a pro…

This study tests the safety of combining the targeted drug alectinib with chemotherapy after surgery for a specific type of lung cancer (ALK-positive non-small cell lung cancer). Eleven patients who had their tumor completely removed will receive up to four cycles of the combinat…

This study tests an experimental drug called BT5528, given alone or with another drug (nivolumab), in people with advanced solid tumors that have high levels of a protein called EphA2. The cancers include ovarian, bladder, lung, breast, head and neck, and stomach cancers. The mai…

This study tests whether adding the cholesterol-lowering drug alirocumab to standard chemotherapy and immunotherapy (cemiplimab) before surgery can help eliminate more cancer cells in people with early-stage non-small cell lung cancer (stages 1B-3A). About 126 adults will be rand…

This study tests a new drug called Ivonescimab in people with non-small cell lung cancer who need surgery. The drug is given before surgery to shrink tumors and make them easier to remove. Researchers compare it to standard treatments and also study how it works in the body. Abou…

This study tests an experimental drug called KIN-2787, taken as a pill, in about 400 adults with advanced solid tumors (like lung cancer or melanoma) that have certain gene changes (BRAF or NRAS). The main goals are to check safety, find the best dose, and see if the drug can shr…

This early-phase study tests a new drug called AB248, alone or with another drug (pembrolizumab), in adults with advanced solid tumors (like lung, skin, head/neck, or kidney cancer) that have not been cured by other treatments. The main goal is to check the drug's safety and find…

This early-phase study tests a personalized cell therapy for people with certain cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, or sarcoma). The therapy takes a patient's own immune cells and genetically equips them to recognize and attack tumors that …

This study tests several targeted therapies for people with advanced or metastatic non-small cell lung cancer (NSCLC) that has specific genetic changes. Instead of a tissue biopsy, a simple blood test is used to find these mutations. The goal is to see if these drugs can shrink t…

This study tests a new oral drug, Mobocertinib, in Japanese adults with non-small cell lung cancer. The first part finds the safest dose, and the second part checks if the drug shrinks tumors. About 53 people will take part, and they may receive treatment for over a year if it he…

This early-stage study tests a new experimental drug (RO7496353) combined with an immunotherapy drug, with or without standard chemotherapy, in people with advanced lung, stomach, or pancreatic cancer. The main goal is to check safety and find the right dose. About 102 participan…

This study tests a new drug called SKB264 in people with advanced solid tumors (like lung, breast, or ovarian cancer) that have not improved with standard treatments. The goal is to find the best dose and see if it can shrink tumors. About 1,410 participants will receive the drug…

This early-phase study tests a new drug called LY4101174 in people with advanced or metastatic solid tumors that have come back or spread. The drug is designed to target and attack cancer cells while sparing healthy ones. The study will check if the drug is safe and what dose wor…

This early-phase trial tests a treatment for adults with metastatic solid tumors (like colorectal, lung, or breast cancer) that have a specific genetic change called KRAS. Doctors take a person's own white blood cells, modify them in a lab to better recognize and attack cancer ce…

This study is testing an experimental drug called AZD5305, a PARP inhibitor, in people with advanced solid tumors like ovarian, breast, pancreatic, and prostate cancer. The goal is to see if the drug is safe and tolerable when given alone or with other cancer treatments. About 70…

This study is for people with advanced solid tumors (like lung or colorectal cancer) that have a specific genetic change called KRAS G12C. It tests a new drug, JDQ443, combined with other treatments to see if they are safe and can shrink tumors. About 74 adults will take part. Th…

This study tests whether the targeted drug osimertinib can prevent early-stage lung cancer from coming back after complete surgical removal. About 390 adults with a specific genetic mutation (EGFR) and stage IA2-IA3 non-small cell lung cancer will receive either osimertinib or a …

This study tests whether combining three drugs—nivolumab, ipilimumab, and nintedanib—can shrink tumors in people with advanced non-small cell lung cancer that cannot be cured. About 66 adults with no other treatment options will receive the drugs to see if the combination is safe…

This study tests whether adding chemotherapy to the targeted drug osimertinib (Tagrisso) works better than osimertinib alone for people with advanced non-small cell lung cancer that has a specific EGFR gene mutation. About 587 adults with newly diagnosed or recurrent advanced lun…

This study tests a new drug called BL-B01D1, given alone or with another drug (osimertinib), in people with advanced non-small cell lung cancer that has spread. The goal is to see if the treatment shrinks tumors and is safe. About 198 adults with this type of lung cancer will tak…

This study tests a new experimental drug, HFB200603, either alone or combined with another cancer drug (tislelizumab), in adults with advanced solid tumors like kidney, lung, skin, stomach, or colorectal cancer. The goal is to find safe doses and understand side effects. About 83…

This study tests whether combining two targeted drugs, osimertinib and gefitinib, is safe and effective for people with advanced EGFR-mutant non-small cell lung cancer. About 48 participants will take both pills daily for up to 6 months. The goal is to see if the combination help…

This study tested giving immunotherapy drugs (nivolumab alone or with ipilimumab) before surgery to people with early-stage non-small cell lung cancer. The goal was to see if it is safe and can shrink tumors before removal. 39 participants received treatment, and researchers look…

This early-stage study tests the safety of a new drug, PF-08046049/SGN-BB228, in people with advanced melanoma and other solid tumors that have spread or are hard to treat. The study involves 41 participants and will look at side effects and the right dose. It is not expected to …

This study tests whether combining two drugs, pembrolizumab and vorinostat, can help people with advanced non-small cell lung cancer. About 120 adults with stage IV disease will receive either the combination or pembrolizumab alone. The goal is to see if the combo is safe and can…

This early-phase study tests a combination of two drugs, ceritinib and docetaxel, in people with advanced non-small cell lung cancer that does not have certain gene changes (ALK-negative, EGFR wild-type). The main goal is to find the safest dose and see if the combination can shr…

This early-stage study tests a new drug called IMT-009 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goals are to find a safe dose and learn about side effects. About 67 participants will receive the drug intravenously,…

This study tests a new drug called SKB264 against standard chemotherapy in 376 adults with advanced non-squamous lung cancer that has a specific EGFR gene change and has stopped responding to targeted therapy. The goal is to see if SKB264 alone can help people live longer without…

This study was planned to test two drugs, Ezabenlimab and BI 907828, in people with advanced solid tumors like sarcoma, lung, breast, colorectal, or bile duct cancer. The goal was to see if the combination could control tumor growth for at least 24 weeks. However, the study was w…

This early-stage study tests an experimental drug called BL-M17D1 in 120 adults with advanced solid tumors that have a specific protein (HER2) or a HER2 gene change. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Participants mus…

This study tests whether a single, powerful dose of targeted radiation (SBRT) is as safe and works as well as the usual multiple doses for people with central non-small cell lung cancer. About 30 adults with early-stage tumors near the chest center will receive one treatment and …

This study tests whether a new drug called ensartinib works better than the current standard drug crizotinib for people with a specific type of advanced lung cancer (ALK-positive NSCLC). About 290 participants who have had up to one prior chemotherapy but no prior ALK-targeted tr…

This study tests a combination of three drugs (zimberelimab, domvanalimab, and etrumadenant) in 30 adults with advanced non-small cell lung cancer who have already received immunotherapy. The goal is to see if the triple therapy can shrink tumors or stop them from growing. Partic…

This study tests a combination of two or three experimental drugs (avutometinib, sotorasib, and defactinib) in people with a specific type of advanced lung cancer called KRAS G12C non-small cell lung cancer. The goal is to see if the combination can shrink tumors and control the …

This study tests whether adding chemotherapy to the targeted drug lazertinib can help people with a specific type of advanced lung cancer (EGFR-mutant non-small cell lung cancer) whose cancer stopped responding to lazertinib alone. About 87 adults will receive the combination and…

This study tests a drug called taletrectinib in people with advanced lung cancer that has a specific genetic change (ROS1 positive). The goal is to see if the drug can shrink tumors and how safe it is. About 217 participants will receive the drug, and researchers will measure res…

This study tests whether the immunotherapy drug atezolizumab can help prevent lung cancer from returning in people with stage IB to IIIA non-small cell lung cancer who have already had surgery and chemotherapy. About 1,280 participants will receive either atezolizumab for 16 cycl…

This study tests whether combining two immunotherapy drugs, durvalumab and oleclumab, can help people with advanced lung cancer that hasn't spread after initial chemoradiation. About 30 adults with stage III non-small cell lung cancer will receive the drug combo. The main goal is…

This study tests a new drug called BL-M02D1 in people with advanced solid tumors, including non-small cell lung cancer that has not responded to standard treatments. The goal is to find the best dose and see if the drug can shrink tumors. About 14 adults will take part in this ea…

This study tests whether a drug called trilaciclib can prevent bone marrow suppression (low blood cell counts) caused by platinum chemotherapy in people with advanced non-small cell lung cancer. About 41 participants will receive trilaciclib before each chemo session. The main go…

This study tests the safety of adding an experimental drug (MPDL3280A) to standard chemotherapy and radiation for people with a type of lung cancer that cannot be removed by surgery. About 52 participants will receive the combination therapy. The main goal is to see how safe the …

This study tests a new drug called DS-1062a in people with advanced solid tumors, including certain lung and breast cancers that have not responded to standard treatments. It is the first time this drug is being used in humans, and the main goals are to check its safety and find …

This study tests a combination of three drugs (amivantamab, lazertinib, and bevacizumab) in 60 people with advanced EGFR-mutant non-small cell lung cancer whose disease worsened after previous treatment. The goal is to see if adding two drugs to a standard targeted therapy can sh…

This early-stage study tests a new drug, RO7247669, that works like a double-pronged key to help the immune system attack cancer cells. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options will r…

This study looks at whether a liquid biopsy (a blood test) can help doctors decide on treatment faster for people with advanced non-small cell lung cancer. About 170 adults with newly diagnosed, advanced lung cancer will have their blood tested for genetic changes. The goal is to…

This study looks at a new technique called OSNA to find tiny cancer deposits in lymph nodes of people with early-stage lung cancer. About 130 patients having robotic lung surgery will be randomly assigned to get either the new OSNA test or the standard lab analysis. The goal is t…

This study tests a new program to help adults with lung cancer improve their quality of life after finishing cancer treatment. About 21 people will take part to see if the program is practical and acceptable. The goal is to support patients as they move from active treatment to r…

This study compares two types of minimally invasive lung surgery for early-stage lung cancer: robotic-assisted and video-assisted (VATS). The goal is to see which one leads to better quality of life and outcomes for patients. About 446 adults with stage I to IIIa non-small cell l…

This study looks at adults with certain cancers (like lung, breast, kidney, or melanoma) that have spread to the brain. All participants are also receiving immunotherapy. The goal is to see if giving a lower dose of radiation over a few days causes fewer side effects than the sta…

This study looks at whether people with certain cancers prefer getting their pembrolizumab as a shot under the skin (subcutaneous) instead of through an IV. About 147 adults with lung cancer, kidney cancer, or melanoma will try both methods and report which they like better. The …

This study tests whether adding acupuncture to standard immunotherapy and chemotherapy can help people with advanced non-small cell lung cancer live longer without their disease getting worse. About 60 participants will receive either real or sham acupuncture alongside their firs…

This study is for people with early-stage lung cancer that can be removed with surgery. Participants receive the immunotherapy drug durvalumab before their operation. The main goal is to see how the drug changes the tumor and immune system, not to cure the disease. About 25 peopl…

This pilot study is testing whether changes in tumor DNA found in the blood can help doctors see if immunotherapy is working in patients with non-small cell lung cancer or kidney cancer. About 100 adults will give blood samples before and during their standard treatment. The goal…

This study examines how often a specific DNA repair issue (HRD) occurs in people with a certain type of advanced lung cancer (EGFR-mutated NSCLC). Researchers will analyze tumor samples from 100 participants to see if this issue is linked to how the cancer behaves. The goal is to…

This study follows 814 people with early-stage non-small cell lung cancer to understand how the cancer changes and spreads over time. By analyzing tumor samples and patient data, researchers aim to find patterns that predict recurrence and improve survival. No new treatment is te…

This study looks at whether PET-CT scans can accurately predict if non-small cell lung cancer has spread to lymph nodes. Researchers will compare scan results with actual tissue samples from surgery in 280 patients. If successful, this could help doctors make better treatment dec…

This study screens up to 1,150 adults with advanced solid tumors (like head and neck, cervical, or lung cancer) to check their genetic markers. Researchers look for specific HLA types and tumor antigens to see if patients might qualify for future cell therapy trials. No treatment…

This study follows over 2,700 patients with bladder, lung, or liver cancer who are receiving the drug atezolizumab as part of their normal care. Researchers are tracking how long patients live and how well the drug controls their cancer outside of a controlled trial setting. The …

This study looks at how tiny genetic differences (called SNPs) in ALK and CYP3A4 genes influence how well the drug alectinib works and what side effects it causes in people with ALK-positive non-small cell lung cancer. Researchers will collect blood samples from 600 patients and …

This study tracks 274 adults with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation). It looks at how well the drug osimertinib works when used as the first treatment in real-life settings, not just in controlled trials. Researchers will follow pa…

This study aims to gather medical history and tissue or saliva samples from 100 people with a specific type of lung cancer called ALK+ non-small cell lung cancer. The goal is to create a registry that helps researchers understand the immune and genetic features of this cancer. Pa…

This study compares two standard treatments for stage I non-small cell lung cancer: surgery and stereotactic body radiation therapy (SBRT). About 446 patients are being followed for up to 3 years to see which treatment leads to better disease-free survival and quality of life. Th…

This study collects white blood cells and tumor samples from up to 7,000 cancer patients and healthy volunteers. The cells are used in the lab to grow large numbers of immune cells that may one day be given back to patients as experimental treatments. Participants do not receive …

This study tracks how doctors use the VeriStrat blood test to make treatment decisions for people with non-small cell lung cancer. Researchers will collect data from about 5,000 patients to see if the test leads to better outcomes. They will also test new experimental blood tests…

This study tests whether a special team of experts (Molecular Tumor Board) can help people with advanced lung cancer live longer and feel better compared to usual care. About 659 adults with stage IIb-IV non-small cell lung cancer who have not yet started treatment will take part…

This study looks at 120 people with suspected or confirmed non-small cell lung cancer who need a tissue sample for genetic testing. Researchers want to see if taking 2 samples from a lymph node works as well as 3 samples for getting enough material for testing. They also check if…

This study looks at the bacteria living in the lungs, airways, and gut of 40 people with non-small cell lung cancer. Half of the participants have surgery only, while the other half also receive chemotherapy. The goal is to understand how these bacteria change and relate to each …

This study looks at whether artificial intelligence can analyze routine brain MRI scans to predict specific genetic changes (EGFR or ALK) in non-small cell lung cancer that has spread to the brain. Researchers will use scans from 380 patients across multiple hospitals to train an…

This study is tracking the safety and effectiveness of the drug XALKORI in 97 people with a certain kind of advanced lung cancer (ROS1-positive non-small cell lung cancer). The main goal is to find any unexpected side effects and see how well the drug works in everyday use. Parti…

This study looks at how PET/CT scans can be used with artificial intelligence to better understand non-small cell lung cancer. Researchers will analyze scans from 500 patients to see if they can predict the cancer's stage, type, gene changes, and how it might progress. The goal i…

This study looks at whether a blood test that detects tiny bits of tumor DNA can help doctors decide when it's safe to stop immunotherapy in people with advanced melanoma or non-small cell lung cancer. About 39 patients who have been on immunotherapy for at least a year and show …

This study looks at tumor samples from over 3,000 people with advanced cancers to find specific genetic markers (biomarkers). The goal is to help doctors choose which targeted therapy clinical trials might work best for each patient. It does not test a new treatment itself, but a…

This study looks back at how patients with non-small-cell lung cancer that has spread only to a few spots in the brain were treated. The goal is to find out which treatment approach leads to the longest time without the cancer growing. The study includes 46 adults treated at two …

This study watches how doctors in Russia treat advanced lung cancer in about 1500 patients. It does not test any new medicine or procedure. Instead, researchers collect information on which treatments are used and how often genetic tests are done. The goal is to understand real-w…

This early trial tests whether using real-time MRI to guide radiation therapy is practical for people with advanced lung cancer. The goal is to see if this personalized approach can reduce side effects and better control tumors. About 30 participants will receive the treatment to…

This study looks at how the heart works during standard treatment for advanced lung cancer. Researchers measured heart function in 231 patients while they walked for six minutes. The goal was to see if heart changes could help predict side effects and survival. This is an observa…